uniQure N.V. Payments of Debt Issuance Costs
uniQure N.V. (QURE) reported Payments of Debt Issuance Costs of $4.29 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-27
- uniQure N.V. payments of debt issuance costs for the quarter ending 2023-12-31 was $0.00.
- uniQure N.V. payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00.
- uniQure N.V. payments of debt issuance costs for fiscal 2023 was $4.29M.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $4.29M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $4.29M 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $4.29M 10-Q · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |